

Table: Demographic and Clinical Characteristics of Contacts with Multidrug-Resistant Latent Tuberculosis Infection (n=31)

		Contacts with MDR-LTBI (n=31)	Did not start treatment for MDR-LTBI (n=5)	Started treatment with LEVO/PZA (n=26)	Completed treatment for MDR-LTBI ³ (n=15)
Gender	Female	16	3	13	9
	Male	15	2	13	6
Age	Mean years	9.6	8.6	9.2	8.8
	(range)	(6-13)	(6-10)	(7-13)	(7-10)
Country of Birth	US-born	28	4	24	14
	Foreign-born	3	1	2	1
Race/Ethnicity	White	29	5	24	14
	Other	2	0	2	1
BCG Vaccination	Yes ¹	4	1	3	1
	No ²	24	3	21	12
	Unknown	3	1	2	2
Started Treatment for MDR-LTBI	Directly Observed Therapy (DOT) at initiation of treatment ⁴			19	
	Self Administered Therapy (SAT) only			7	
Completed Treatment for MDR-LTBI (%)	DOT at initiation of treatment (%)				12 (63) ⁵
	SAT only (%)				3 (43) ⁶

¹ all foreign-born and 1 US-born contacts had a history of bacilli Calmette-Guerin (BCG) vaccination

² 6 US-born contacts with unknown history of BCG vaccination and no opportunity for overseas BCG vaccination were included in the “NO” BCG category

³ of contacts started on multidrug-resistant latent tuberculosis infection (MDR-LTBI) treatment

⁴ DOT ranged from 1 day to 4 months. On average, contacts were on DOT for 3 months before changing to SAT secondary to the school year ending

⁵ of contacts started on MDR-LTBI treatment by directly observed therapy (DOT)

⁶ of contacts started on MDR-LTBI treatment by self-administered therapy (SAT)